Business Wire

Breakthrough Discovery: British Explorer Andrew ‘Sandy’ Irvine’s Partial Remains Believed to Be Found on Mount Everest After 100 Years

11.10.2024 08:00:00 CEST | Business Wire | Press release

Share

Discovery Made by Expedition Team Led by Jimmy Chin During Mount Everest Climb for Upcoming National Geographic Documentary Film, Reported Exclusively on NatGeo.comEvidence Is First Possible Proof of Irvine’s Death Since Disappearing During 1924 Expedition With George Mallory, Whose Remains Were Found on Everest in 1999 by Conrad AnkerExclusive Photos NatGeo.com Story: https://www.nationalgeographic.com/adventure/article/sandy-irvine-body-found-everest

After 100 years of speculation surrounding his fate, the partial remains of Andrew Comyn “Sandy” Irvine are believed to have finally been discovered on Mount Everest. At age 22, Irvine vanished while attempting to conquer the world’s tallest peak on June 8, 1924, along with his climbing partner, renowned mountaineer George Mallory.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010214459/en/

A sock embroidered with "A.C. Irvine", along with a boot, has been discovered on the Central Rongbuk Glacier below the North Face of Mount Everest by a team led by Jimmy Chin. This is the first possible proof of Irvine's death since disappearing during a 1924 expedition. (credit: Jimmy Chin)

The discovery was made recently by a small team including National Geographic Explorer, photographer, Academy Award-winning director and professional climber Jimmy Chin along with climbers and filmmakers Erich Roepke and Mark Fisher. What is believed to be Irvine’s foot, encased in a sock and boot, was found on the Central Rongbuk Glacier below the North Face of Everest at a lower altitude than Mallory’s remains were located. The partial remains – identified with his name stitched into the sock – are now in the possession of the China Tibet Mountaineering Association, which is responsible for climbing permits on Everest’s northern side.

The find was reported to the Royal Geographical Society - who jointly organized Mallory and Irvine’s expedition along with the Alpine Club - which at the time was only the third British climb on Mount Everest. It was also shared with Irvine’s great niece and biographer, Julie Summers – one of many living family relatives. The Irvine family has volunteered to compare DNA test results with the remains to confirm Irvine’s identity.

“Any expedition to Everest follows in the shadow of Irvine and Mallory,” said Chin. “We certainly did. And sometimes in life the greatest discoveries occur when you aren’t even looking. This was a monumental and emotional moment for us and our entire team on the ground, and we just hope this can finally bring peace of mind to his relatives and the climbing world at large.”

“It is remarkable that this discovery was made in the centenary year of Sandy’s disappearance,” said Summers. “I have lived with this story since I was a 7-year-old when my father told us about the mystery of Uncle Sandy on Everest. The story became more real when climbers found the body of George Mallory in 1999, and I wondered if Sandy’s body would be discovered next. A quarter of a century after that discovery, it seemed extremely unlikely that anything new would be found. When Jimmy told me that he saw the name A.C. Irvine on the label on the sock inside the boot, I found myself moved to tears. It was and will remain an extraordinary and poignant moment.”

Professor Joe Smith, director of the Royal Geographical Society, said of the discovery: “As joint organiser of the 1924 Everest expedition (with the Alpine Club), the Society deeply appreciates the respect Jimmy Chin’s team has shown Sandy Irvine’s remains and their sensitivity toward Sandy’s family members and others connected to that expedition. Sandy was an exceptional figure and made a significant contribution to our understanding of Everest and the Himalaya. This discovery of his remains provides an element of closure for his relatives and the wider mountaineering community, and we are grateful to Jimmy and his team for enabling this and ensuring Sandy is in safe hands. The Society will continue to assist Jimmy, his team and Sandy’s extended family during what will inevitably be a period of intense global interest.”

Irvine and Mallory were British mountaineers who disappeared in 1924 during an expedition organized by the Royal Geographical Society and Alpine Club to be the first to summit Everest. The mystery of whether they reached the summit before their death has intrigued climbers and historians for decades. Mallory’s body was discovered in 1999 by climber Conrad Anker, but until now, Irvine’s remains had never been found.

The team’s climb was funded by National Geographic Documentary Films for an upcoming documentary directed and produced by the Academy Award- and the BAFTA Award-winning team behind “Free Solo,” E. Chai Vasarhelyi and Chin, and their banner Little Monster Films.

Irvine Family Statement on the Discovery:

“The Irvine family is deeply moved to hear of the discovery of partial remains of Sandy Irvine. We are grateful to the mountaineering and film team, led by Jimmy Chin, who made the discovery and who have treated it with respect and professionalism. We are happy that the remains are now in the hands of the CTMA. Sandy Irvine was the youngest member of the 1924 Mount Everest expedition and was lost on the upper slopes of the mountain with George Mallory when the two disappeared on 8 June 1924.”

ABOUT JIMMY CHIN

Chin is a professional climber, skier, mountaineer, 20-year member of The North Face Athlete Team and National Geographic Explorer. Consistently over the past 20 years, Chin has led or participated in cutting-edge climbing and ski mountaineering expeditions to all seven continents and participated in the first and only American ski descent from the summit of Mount Everest. He is also a filmmaker and National Geographic photographer. He has worked with many of the greatest explorers, adventurers and athletes of our time, documenting their exploits in the most challenging conditions and locations in the world. Together with his wife, Elizabeth Chai Vasarhelyi, he has co-directed the films “Meru,” “Free Solo,” “The Rescue,” “Wild Life,” “Return To Space,” and their first scripted feature, “Nyad.” Their next documentary feature, “Endurance” premieres this weekend at the BFI London Film Festival. Chin and Vasarhleyi won the Best Documentary Oscar® in 2019 for “Free Solo.”

Exclusive Photos
NatGeo.com Story:
https://www.nationalgeographic.com/adventure/article/sandy-irvine-body-found-everest

View source version on businesswire.com: https://www.businesswire.com/news/home/20241010214459/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release

The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn

Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release

CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a

Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release

Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2

Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release

Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar

Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release

Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye